For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Pharmacy…working on the margins
Wednesday 12 September 2018, 06:00 AM

Declaration of interest: Anna Mickell is a director of The Health Media, publishers of New Zealand Doctor and Pharmacy Today
Community pharmacy is in the process of deciding whether to access a new services agreement on offer from DHBs. Pharmacy sector commentator Anna Mickell argues the new agreement does not go far enough to relieve pharmacy’s reliance on non-pharmacy products and services to stay viable
The cost and risk of managing the inventory and distribution of 45 million-plus funded prescription items per year were passed from DHBs to diversifie
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.